Skye Bioscience Inc
NASDAQ:SKYE
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1.55
18
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Skye Bioscience Inc
Common Shares Outstanding
Skye Bioscience Inc
Common Shares Outstanding Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Common Shares Outstanding | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Skye Bioscience Inc
NASDAQ:SKYE
|
Common Shares Outstanding
$30.3m
|
CAGR 3-Years
152%
|
CAGR 5-Years
124%
|
CAGR 10-Years
90%
|
||
Abbvie Inc
NYSE:ABBV
|
Common Shares Outstanding
$1.8B
|
CAGR 3-Years
0%
|
CAGR 5-Years
4%
|
CAGR 10-Years
1%
|
||
Gilead Sciences Inc
NASDAQ:GILD
|
Common Shares Outstanding
$1.2B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-2%
|
||
Amgen Inc
NASDAQ:AMGN
|
Common Shares Outstanding
$537.5m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-3%
|
||
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Common Shares Outstanding
$257.7m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
1%
|
||
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Common Shares Outstanding
$110.1m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
1%
|
Skye Bioscience Inc
Glance View
Skye Bioscience, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of cannabinoid-based therapeutics. The company is headquartered in San Diego, California and currently employs 9 full-time employees. The company went IPO on 2014-02-24. The Company’s products programs include THCVHS and CBDVHS. The firm's lead candidate, THCVHS, is a prodrug of tetrahydrocannabinol (THC), is a topical formulation under development for the treatment of glaucoma and ocular hypertension (OHT). The company chemically modifies THC to create a unique synthetic molecule with the intent to realize the known positive effects of THC. Its molecule enables enhanced local delivery in the eye, reduced systemic side effects, and the potential for neuroprotection for the treatment of ocular diseases. CBDVHS is a proprietary analog of cannabidiol (CBD) that has demonstrated biological activity that is both pharmacologically and therapeutically distinct from CBD in various preclinical models.
See Also
What is Skye Bioscience Inc's Common Shares Outstanding?
Common Shares Outstanding
30.3m
USD
Based on the financial report for Sep 30, 2024, Skye Bioscience Inc's Common Shares Outstanding amounts to 30.3m USD.
What is Skye Bioscience Inc's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 10Y
90%
Over the last year, the Common Shares Outstanding growth was 146%. The average annual Common Shares Outstanding growth rates for Skye Bioscience Inc have been 152% over the past three years , 124% over the past five years , and 90% over the past ten years .